Latest 10-Q quarterly reports

CorMedix Inc. announced a substantial increase in revenue and net income for the second quarter of 2026, primarily fueled by the integration of Melinta Therapeutics and robust sales of DefenCath.

Bit Digital Inc. filed its Q2 2026 report, detailing a significant net loss of $111.7 million, a substantial decrease in digital asset holdings, and notable impairments on digital intangible assets, despite revenue growth in its cloud services segment.

Amanat Acquisition Corp reports on its financial condition and operational status for the quarter ended June 30, 2026, highlighting its ongoing search for a business combination.

Maitong Sunshine Cultural Development Co., Limited's Q3 2026 report shows a 100% revenue decline for the quarter and a 98% drop year-to-date, alongside a significant increase in net loss.

Aimei Health Technology Co., Ltd. announced the termination of its business combination with United Hydrogen Group Inc. and faces substantial doubt regarding its ability to continue as a going concern.

Pyxis Oncology reports continued operating losses and substantial R&D expenses, raising concerns about its ability to continue as a going concern despite a recent private placement.

Karyopharm Therapeutics Inc. reported substantial doubt about its ability to continue as a going concern, citing significant operating losses and upcoming debt obligations, despite a slight increase in net product revenue.

Indaptus Therapeutics reports substantial net losses and cash burn, while pivoting strategy to explore acquisitions and research collaborations, raising going concern doubts.

Cabaletta Bio reports increased R&D expenses and continued net losses, highlighting substantial doubt about its ability to continue as a going concern and the need for significant future financing.

Falcons Beyond Global, Inc. filed its Q2 2026 10-Q, revealing increased revenue driven by its Attractions business but also highlighting substantial doubt about its ability to continue as a going concern.

FitLife Brands, Inc. announced a 65% increase in Q2 revenue, primarily driven by the Irwin Naturals acquisition, despite a decline in its legacy business and a reduced gross margin.

Grace Therapeutics Inc. reported its Q2 2026 financial results, highlighting a net loss of $15.79 million and a significant impairment charge, while continuing efforts to address FDA feedback on its lead drug candidate, GTx-104.

Advanced Flower Capital Inc. (AFCG) reported its Q2 2026 results, highlighting a successful transition to a BDC structure and improved net investment income, while navigating challenges in its loan portfolio.

Abeona Therapeutics Inc. reported its second quarter 2026 financial results, highlighting $11.4 million in product revenue from ZEVASKYN, while also disclosing ongoing operational losses and manufacturing hurdles.

Cocrystal Pharma, Inc. reported its second quarter 2026 financial results, highlighting ongoing research and development efforts but also substantial net losses and a critical need for future financing.

Pelthos Therapeutics Inc. filed its Q2 2026 Form 10-Q, detailing a substantial net loss, a material weakness in financial reporting, and updates on its product portfolio and financing.

Avai Bio, Inc. (AVAI) filed its Q2 2026 10-Q, revealing no revenue, increased net losses, and significant concerns regarding its ability to continue as a going concern.

Spire Global's Q2 2026 results show a 6% revenue decline year-over-year, driven by the sale of its maritime business, alongside increased cost of revenue and operating expenses, impacting gross margin.

McGraw Hill's Q2 2026 results show a 2.6% revenue increase to $549.9 million and a significant jump in net income to $57.9 million, driven by Higher Education and K-12 segments.

Zenas BioPharma reported increased operating expenses and net losses in its Q2 2026 10-Q filing, alongside progress in its late-stage clinical trials for immunology and inflammation therapies.

BK Technologies Corporation announced its second quarter 2026 financial results, showcasing a 10.6% increase in net sales and improved gross profit margins, driven by strong performance in its BKR series radios.

Venu Holding Corporation reported a wider net loss for Q2 2026, driven by increased operating costs and significant investments in new venue development, although total revenues saw a modest increase.

Charlotte's Web Holdings, Inc. reported a 15.2% decrease in revenue for the three months ended June 30, 2026, alongside a net loss of $4.1 million.

Pelthos Therapeutics Inc. has filed an amendment to its Q1 2026 report to restate financial statements due to errors in convertible debt valuation, revealing a material weakness in internal controls.

SBC Medical Group Holdings Incorporated announced a significant increase in revenue and net income for the second quarter of 2026, driven by strong performance in management services and the inclusion of the Waqoo segment.

Cellectar Biosciences reported increased R&D spending and positive clinical trial data for iopofosine I 131, but faces substantial doubt regarding its ability to continue as a going concern.

Aveanna Healthcare Holdings Inc. announced a significant increase in revenue and net income for the second quarter ended July 4, 2026, driven by strong performance across its segments and strategic acquisitions.

Aebi Schmidt Holding AG's Q2 2026 results show a substantial revenue surge and improved profitability, largely due to the integration of The Shyft Group, despite ongoing internal control remediation.

Rockwell Medical's Q2 2026 Form 10-Q filing reveals a slight increase in net sales and improved gross profit, but continued net losses, with management highlighting efforts towards sustainable profitability and potential capital raises.

Hepion Pharmaceuticals' Q2 2026 report highlights significant operating losses, a substantial accumulated deficit, and material weaknesses in internal controls, raising concerns about its ability to continue as a going concern despite recent financing.